Pfizer (NYSE: PFE) has become a tantalizing yet potentially perilous option for dividend investors. With its stock price down 31% over the past five years and a current dividend yield of 7%, the pharmaceutical giant now offers one of the most attractive payouts in the healthcare sector. For income-seeking investors comparing bond yields of 4% to 5%, Pfizer’s dividend may seem irresistible.
However, investors should caution whether this is a “value trap” disguised as a high-yield opportunity.
Pfizer’s quarterly dividend of $0.43 per share translates to an annualized $1.72, yielding 7% at the current share price of approximately $25. The company has paid dividends for 345 consecutive quarters and raised them annually for 16 years, though recent increases have been minimal—just 2.4% for 2025, lifting the quarterly payout from $0.42 to $0.43. Notably, Pfizer froze its dividend in 2010 during the integration of its Wyeth acquisition, demonstrating that management prioritizes financial health when necessary.
The payout ratio provides deeper insight. After spiking above 100% during the COVID-19 revenue collapse—when sales of vaccines and Paxlovid plummeted from their $90 billion peak—the ratio has moderated to 89% based on trailing earnings. Management projects adjusted earnings per share of $2.90 to $3.10 for 2025, which would lower the payout ratio to a more sustainable range of 55% to 59%, assuming mid-point guidance is achieved.
Pfizer faces a patent cliff for key drugs: Ibrance (2027), Eliquis (2028), and Vyndaqel (in coming years). Products facing loss of exclusivity represent nearly 30% of Pfizer’s current annual revenue. Although management has launched a $7.2 billion cost-cutting program, these measures may not fully offset structural revenue declines.
Optimists point to Pfizer’s $43 billion acquisition of Seagen as a pipeline revitalization strategy. The oncology-focused biotech brings promising antibody-drug conjugate technology, with bladder cancer drug Padcev expected to drive growth. Management projects Seagen will generate $10 billion in revenue by 2030, though Wall Street estimates are closer to $7-$8 billion.
The internal pipeline is less encouraging: The discontinuation of obesity drug danuglipron due to liver toxicity concerns caused Pfizer to miss out on a potential $200 billion market by 2031. COVID-related products have stabilized at $5-$6 billion in annual revenue but lack growth catalysts. Recent FDA authorizations restricting vaccine use to high-risk populations further limit upside. Programs like RSV vaccines, mRNA flu shots, and combination vaccines (flu + COVID) are in late-stage trials but are seen as incremental rather than transformative commercially.
Pfizer trades at just 8.1 times forward earnings, reflecting market skepticism. Wall Street projects annual earnings declines of 3% through 2029, undermining dividend growth prospects. By comparison, Johnson & Johnson offers a 2.9% yield with a fortress balance sheet, AbbVie yields 3.1% with its Humira biosimilar transition largely complete, and Merck provides a 3.9% yield with Keytruda still growing rapidly. These peers offer lower yields but greater dividend security.
Based on current cash flow, Pfizer’s dividend appears safe through at least 2026. However, as patent losses accelerate and pipeline uncertainties persist, the board will face difficult decisions. A dividend cut is not imminent, but meaningful growth is unlikely. The dividend’s safety is medium-term strong but long-term questionable.
Buying Pfizer solely for its dividend is a bet that management can simultaneously navigate patent cliffs, pipeline setbacks, potential high-value acquisitions in obesity, and cost restructuring. The 7% yield compensates investors for real risks rather than abundant free cash flow.
